Published in Kidney Int on April 17, 2013
Microparticles: markers and mediators of sepsis-induced microvascular dysfunction, immunosuppression, and AKI. Kidney Int (2015) 1.09
Bridging Translation by Improving Preclinical Study Design in AKI. J Am Soc Nephrol (2015) 0.95
Sirt1 deletion leads to enhanced inflammation and aggravates endotoxin-induced acute kidney injury. PLoS One (2014) 0.94
Inhibition of IκB kinase reduces the multiple organ dysfunction caused by sepsis in the mouse. Dis Model Mech (2013) 0.93
Nonredundant protective properties of FPR2/ALX in polymicrobial murine sepsis. Proc Natl Acad Sci U S A (2014) 0.91
Evaluation of urinary tissue inhibitor of metalloproteinase-2 in acute kidney injury: a prospective observational study. Crit Care (2014) 0.86
Quantification of microcirculatory blood flow: a sensitive and clinically relevant prognostic marker in murine models of sepsis. J Appl Physiol (1985) (2014) 0.86
A non-erythropoietic peptide derivative of erythropoietin decreases susceptibility to diet-induced insulin resistance in mice. Br J Pharmacol (2014) 0.86
Association of inflammatory and endothelial cell activation biomarkers with acute kidney injury after sepsis. Springerplus (2014) 0.84
ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response. Mol Pain (2014) 0.81
IκB Kinase Inhibitor Attenuates Sepsis-Induced Cardiac Dysfunction in CKD. J Am Soc Nephrol (2016) 0.80
Erythropoietin reduces acute lung injury and multiple organ failure/dysfunction associated to a scald-burn inflammatory injury in the rat. Inflammation (2015) 0.80
Tissue protection by erythropoietin: new findings in a moving field. Kidney Int (2013) 0.80
β Common Receptor Mediates Erythropoietin-Conferred Protection on OxLDL-Induced Lipid Accumulation and Inflammation in Macrophages. Mediators Inflamm (2015) 0.78
Elevation of serum sphingosine-1-phosphate attenuates impaired cardiac function in experimental sepsis. Sci Rep (2016) 0.78
Efficacy and Safety of Erythropoietin to Prevent Acute Kidney Injury in Patients With Critical Illness or Perioperative Care: A Systematic Review and Meta-analysis of Randomized Controlled Trials. J Cardiovasc Pharmacol (2015) 0.76
Carbamylated Erythropoietin Outperforms Erythropoietin in the Treatment of AKI-on-CKD and Other AKI Models. J Am Soc Nephrol (2016) 0.76
Restricted Use of Erythropoiesis-Stimulating Agent is Safe and Associated with Deferred Dialysis Initiation in Stage 5 Chronic Kidney Disease. Sci Rep (2017) 0.75
Dual inhibiting senescence and epithelial-to-mesenchymal transition by erythropoietin preserve tubular epithelial cell regeneration and ameliorate renal fibrosis in unilateral ureteral obstruction. Biomed Res Int (2013) 0.75
Renoprotective effect of erythropoietin in zebrafish after administration of gentamicin: an immunohistochemical study for β-catenin and c-kit expression. J Nephrol (2016) 0.75
Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science (2004) 4.09
Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med (2002) 3.87
Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A (2004) 3.40
Failed asylum seekers and health care. BMJ (2006) 2.69
Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol (2004) 2.64
Abandon the mouse research ship? Not just yet! Shock (2014) 2.60
Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med (2003) 2.37
Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci (2005) 2.32
Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A (2003) 2.28
Chinese herbal uropathy and nephropathy. Lancet (2006) 2.27
Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci U S A (2008) 2.21
Is structured observation a valid technique to measure handwashing behavior? Use of acceleration sensors embedded in soap to assess reactivity to structured observation. Am J Trop Med Hyg (2010) 2.17
Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci U S A (2002) 2.16
Ischemic conditioning protects the uremic heart in a rodent model of myocardial infarction. Circulation (2012) 2.12
Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci U S A (2002) 2.08
Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci U S A (2011) 2.07
GSK-3beta inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat. Crit Care Med (2005) 2.05
Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res (2002) 2.04
Performance of anal cytology in a clinical setting when measured against histology and high-resolution anoscopy findings. AIDS (2010) 1.92
Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci U S A (2003) 1.88
On the selectivity of superoxide dismutase mimetics and its importance in pharmacological studies. Br J Pharmacol (2003) 1.77
Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J (2002) 1.73
Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci U S A (2002) 1.66
Insulin reduces the multiple organ injury and dysfunction caused by coadministration of lipopolysaccharide and peptidoglycan independently of blood glucose: role of glycogen synthase kinase-3beta inhibition. Crit Care Med (2006) 1.66
Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci U S A (2004) 1.65
Presentation, diagnosis, and treatment outcome of tuberculous-mediated tubulointerstitial nephritis. Kidney Int (2010) 1.64
Anti-apoptotic and anti-inflammatory effects of hydrogen sulfide in a rat model of regional myocardial I/R. Shock (2009) 1.60
Peptidoglycan of Staphylococcus aureus causes inflammation and organ injury in the rat. Crit Care Med (2004) 1.57
Role of inducible nitric oxide synthase in the reduced responsiveness of the myocardium to catecholamines in a hyperdynamic, murine model of septic shock. Crit Care Med (2006) 1.54
Nitrite-derived nitric oxide protects the rat kidney against ischemia/reperfusion injury in vivo: role for xanthine oxidoreductase. J Am Soc Nephrol (2007) 1.53
Enhanced IL-17 signalling following myocardial ischaemia/reperfusion injury. Int J Cardiol (2011) 1.52
Pyrrolidine dithiocarbamate attenuates the development of organ failure induced by zymosan in mice. Intensive Care Med (2003) 1.52
Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation. Eur J Pharmacol (2004) 1.50
Generation of endogenous hydrogen sulfide by cystathionine gamma-lyase limits renal ischemia/reperfusion injury and dysfunction. Lab Invest (2008) 1.49
Effects of calpain inhibitor I on multiple organ failure induced by zymosan in the rat. Crit Care Med (2002) 1.49
Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces the development of nonseptic shock induced by zymosan in mice. Crit Care Med (2004) 1.48
Refinement of animal models of sepsis and septic shock. Shock (2015) 1.48
Pyrrolidine dithiocarbamate attenuates the development of acute and chronic inflammation. Br J Pharmacol (2002) 1.47
Inhibition of endogenous hydrogen sulfide formation reduces the organ injury caused by endotoxemia. Br J Pharmacol (2005) 1.45
In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion. Clin Cancer Res (2006) 1.42
Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock. Cardiovasc Res (2005) 1.41
Endogenous interleukin-6 enhances the renal injury, dysfunction, and inflammation caused by ischemia/reperfusion. J Pharmacol Exp Ther (2004) 1.39
Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Mol Med (2012) 1.33
The cyclopentenone prostaglandin 15-deoxy-Delta(12,14)-prostaglandin J(2) attenuates the development of acute and chronic inflammation. Mol Pharmacol (2002) 1.29
Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5. J Endocrinol (2010) 1.28
The effect of a soap promotion and hygiene education campaign on handwashing behaviour in rural India: a cluster randomised trial. Trop Med Int Health (2009) 1.27
Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis. J Neuroimmunol (2005) 1.26
Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo. Kidney Int (2004) 1.26
A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci U S A (2005) 1.24
Glycogen synthase kinase 3beta as a target for the therapy of shock and inflammation. Shock (2007) 1.23
Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives. J Cereb Blood Flow Metab (2006) 1.21
Nonhematopoietic erythropoietin derivatives prevent motoneuron degeneration in vitro and in vivo. Mol Med (2006) 1.21
Sampling results of the improved SKC diesel particulate matter cassette. J Occup Environ Hyg (2005) 1.21
The receptor that tames the innate immune response. Mol Med (2012) 1.19
Erythropoietin as a tissue-protective cytokine in brain injury: what do we know and where do we go? Neuroscientist (2004) 1.18
TNF receptor I sensitizes neurons to erythropoietin- and VEGF-mediated neuroprotection after ischemic and excitotoxic injury. Proc Natl Acad Sci U S A (2008) 1.17
Noncleavable poly(ADP-ribose) polymerase-1 regulates the inflammation response in mice. J Clin Invest (2004) 1.17
Dexamethasone ameliorates renal ischemia-reperfusion injury. J Am Soc Nephrol (2009) 1.17
Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion: effects of the PPAR-alpha agonist WY14643. Free Radic Biol Med (2006) 1.16
Recognition of citrullinated and carbamylated proteins by human antibodies: specificity, cross-reactivity and the 'AMC-Senshu' method. Ann Rheum Dis (2012) 1.16
GW274150, a potent and highly selective inhibitor of iNOS, reduces experimental renal ischemia/reperfusion injury. Kidney Int (2003) 1.16
PPARgamma stimulation promotes mitochondrial biogenesis and prevents glucose deprivation-induced neuronal cell loss. Neurochem Int (2009) 1.15
Protective effect of erythropoietin and its carbamylated derivative in experimental Cisplatin peripheral neurotoxicity. Clin Cancer Res (2006) 1.15
Inhibition of inducible nitric oxide synthase reduces renal ischemia/reperfusion injury. Kidney Int (2002) 1.15
Lipoproteins in inflammation and sepsis. I. Basic science. Intensive Care Med (2006) 1.14
Cardioprotection by a nonerythropoietic, tissue-protective peptide mimicking the 3D structure of erythropoietin. Proc Natl Acad Sci U S A (2010) 1.14